Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Support
This activity is supported by educational grants from Blueprint Medicines, Exelixis, and Lilly.
Community Practice Connections™: Addressing Clinical Gaps in Thyroid Cancer Management: New Agents, New Testing Paradigms, and Methods to Facilitate Multidisciplinary Care and Coordination
Release Date: July 22, 2021
Expiration Date: July 22, 2022
Activity Overview
Thyroid cancer is the most common malignancy of the endocrine system, and it represents a broad heterogeneity of disease. In the past several years, a greater understanding of the pathogenesis of these thyroid cancer subtypes has led to a number of new and emerging agents that have revolutionized the treatment of these malignancies.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 2021 ASCO Annual Meeting, held in June 2021. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with thyroid cancer, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Blueprint Medicines, Exelixis, and Lilly.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational activity is directed toward endocrinologists and radiation, surgical, and medical oncologists interested in the treatment of thyroid cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with thyroid cancer are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the impact of genetic testing in diagnosis and treatment decision making in thyroid cancer
- Evaluate the clinical profiles of current and emerging targeted therapies for the treatment of patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) and advanced medullary thyroid cancer (MTC)
- Translate results from landmark trials evaluating targeted agents in thyroid cancer into personalized treatment plans with a focus on multidisciplinary care optimization
- Implement proactive strategies to identify and manage treatment-related toxicities in patients with RAI-refractory DTC and advanced MTC
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Program Chair
Professor of Medicine and Otorhinolaryngology
Head and Neck Surgery
Hospital of the University of Pennsylvania
Philadelphia, PA
Disclosures: Grant Research Support: Bayer Healthcare, Blueprint Medicines, Eisai, Exelixis, Loxo Oncology, Novartis Pharmaceuticals; Consultant: Bayer HealthCare, Eisai, Exelixis, Loxo Oncology; Other: Honoraria: Bayer Healthcare, Eisai.
Faculty
Professor of Medicine (Hematology/Oncology)
Director, Hematology/Oncology Fellowship Program
Vanderbilt University Medical Center
Nashville, TN
Disclosures: Grant Research Support: Exelixis; Consultant: Bayer, Exelixis.
Associate Professor of Clinical Pathology and Laboratory Medicine
Clinical Director, Center for Personalized Diagnostics
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
Disclosures: Consultant: Bayer Healthcare, Novartis Pharmaceuticals; Speakers’ Bureau: National Comprehensive Cancer Network; Stock/Shareholder: Thermo Fisher Scientific.
Clinical investigator
Multidisciplinary Head and Neck Oncology
Multidisciplinary Lung Cancer
University of Michigan Rogel Cancer Center
Ann Arbor, MI
Disclosures: Grant Research Support: Bayer, Bristol Myers Squibb, Cue Biopharma, Lilly, Merck; Consultant: Bristol Myers Squibb, Eisai, Exelixis, Merck.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
